S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

$6.50
-0.25 (-3.70%)
(As of 03/18/2024 ET)
Today's Range
$6.35
$6.98
50-Day Range
N/A
52-Week Range
$4.00
$9.56
Volume
259,950 shs
Average Volume
199,931 shs
Market Capitalization
$180.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.15

Actinium Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
302.3% Upside
$26.15 Price Target
Short Interest
Bearish
6.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Actinium Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.06) to ($1.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

ATNM stock logo

About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

ATNM Stock Price History

ATNM Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
See More Headlines
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/03/2023
Today
3/18/2024
Next Earnings (Estimated)
3/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:ATNM
CIK
N/A
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.15
High Stock Price Target
$50.00
Low Stock Price Target
$11.60
Potential Upside/Downside
+302.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-33,020,000.00
Pretax Margin
-102,975.55%

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
$2.61 per share

Miscellaneous

Free Float
26,653,000
Market Cap
$180.44 million
Optionable
Not Optionable
Beta
0.01
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Sandesh C. Seth M.B.A. (Age 60)
    M.S., Chairman & CEO
    Comp: $1.15M
  • Mr. Steven O'Loughlin BS (Age 38)
    CFO & Corporate Secretary
    Comp: $585k
  • Dr. Paul Diamond Esq.
    Ph.D., Vice President of Patent & Legal Counsel
  • Dr. David Gould
    Senior Vice President of Corporate Development & Corporate Affairs
  • Dr. Bernie Cunningham P.M.P.
    Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang
    VP & Head of Radiation Sciences
  • Dr. Avinash Desai M.D.
    Chief Medical Officer
  • Ms. Jenny Hsieh
    Chief Strategy Officer
  • Ms. Sunitha Lakshminarayanan
    Senior VP, Head of CMC & Product Development
  • Ms. Elaina Haeuber
    VP & Head of Clinical Operations

ATNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares.
View ATNM analyst ratings
or view top-rated stocks.

What is Actinium Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 1 year price objectives for Actinium Pharmaceuticals' stock. Their ATNM share price targets range from $11.60 to $50.00. On average, they predict the company's share price to reach $26.15 in the next year. This suggests a possible upside of 302.3% from the stock's current price.
View analysts price targets for ATNM
or view top-rated stocks among Wall Street analysts.

How have ATNM shares performed in 2024?

Actinium Pharmaceuticals' stock was trading at $5.24 on January 1st, 2024. Since then, ATNM shares have increased by 24.0% and is now trading at $6.50.
View the best growth stocks for 2024 here
.

When is Actinium Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Sunday, March 31st 2024.
View our ATNM earnings forecast
.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) posted its quarterly earnings data on Monday, April, 3rd. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.01.

When did Actinium Pharmaceuticals' stock split?

Actinium Pharmaceuticals shares reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.91%), Vanguard Group Inc. (4.91%), Northern Trust Corp (0.82%), Dimensional Fund Advisors LP (0.53%), Bridgeway Capital Management LLC (0.30%) and Barclays PLC (0.14%).
View institutional ownership trends
.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ATNM) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners